Your browser doesn't support javascript.
loading
N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
Jang, In Sung; Yoon, Won Kyoung; Choi, Eun Wha.
Affiliation
  • Jang IS; Department of Veterinary Clinical Pathology, College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, 1 Kangwondaehak-Gil, Chuncheon, Gangwon-Do, 24341, Republic of Korea.
  • Yoon WK; Guardian Angel Veterinary Hospital, 552, Gyeongsudae-Ro, Dongan-Gu, Anyang-Si, Gyeonggi-Do, 14112, Republic of Korea.
  • Choi EW; Department of Veterinary Clinical Pathology, College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, 1 Kangwondaehak-Gil, Chuncheon, Gangwon-Do, 24341, Republic of Korea. ewchoi@kangwon.ac.kr.
Ir Vet J ; 76(1): 3, 2023 Feb 08.
Article in En | MEDLINE | ID: mdl-36755290
BACKGROUND: Systemic hypertension affects the heart, and to the best of our knowledge, no study has investigated the effects of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in dogs with myxomatous mitral valve disease (MMVD) stage B and systemic hypertension. This study aimed to investigate the blood level of NT-proBNP and assess the selected echocardiographic variables in dogs with MMVD stage B according to the presence of systemic hypertension or normal blood pressure and in dogs without MMVD. RESULTS: The study group comprised 37 dogs with stage B MMVD (normotensive group, n = 30; systemic hypertension group, n = 7) and 13 dogs without MMVD. We evaluated NT-proBNP, blood pressure, complete blood count (CBC), and serum chemistry in all 50 dogs. We performed electrocardiography, radiography, and echocardiography on 44 dogs (37 dogs with MMVD and 7 dogs without MMVD). The NT-proBNP concentrations showed significant intergroup differences (p < 0.001). Normotensive dogs with MMVD stage B (median [interquartile range]: 1083.5 [574.8-1912.8] pmol/L) and hypertensive dogs with MMVD stage B (2345.0 [1812.5-2533.0] pmol/L) showed significantly higher NT-proBNP concentrations than dogs without MMVD (504 [430-774] pmol/L, p = 0.009 and p < 0.001, respectively), and dogs in the systemic hypertension group showed significantly higher NT-proBNP concentrations than those in the normotensive group (p = 0.046). Mitral valve regurgitation velocity was significantly higher in dogs in the systemic hypertension group (6.11 [6.07-6.24] m/s) than in those in the normotensive group (5.53 [5.17-5.95] m/s, p = 0.006). The left atrial to aortic root ratio (LA/Ao), E-peak velocity, and left ventricular end-diastolic internal diameter corrected for body weight (LVIDDN) were significantly lower in dogs without MMVD than in dogs with MMVD stage B. CONCLUSIONS: These findings suggest that NT-proBNP concentrations are higher in dogs with MMVD stage B with systemic hypertension than in normotensive dogs with MMVD stage B. Therefore, clinicians should be aware that NT-proBNP could be elevated in the presence of systemic hypertension.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ir Vet J Year: 2023 Document type: Article Country of publication: Ireland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ir Vet J Year: 2023 Document type: Article Country of publication: Ireland